Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early ER/PR Negative Breast Cancer.

Trial Profile

Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early ER/PR Negative Breast Cancer.

Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 27 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top